WW International announced a partnership with PVOLVE, a clinically validated strength‑training company, to provide members with exclusive access to PVOLVE’s library of more than 1,700 on‑demand classes covering strength, mobility, and stability. The collaboration is available across WW’s Core, Core+, Med+, GLP‑1 Success, and Menopause programs, and members who wish to exercise at home receive a starter kit of resistance equipment.
The partnership is strategically designed to preserve lean muscle mass, a critical factor for long‑term weight management and for patients on GLP‑1 medications. By integrating movement into its already comprehensive ecosystem—behavioral coaching, nutrition guidance, and medical support—WW aims to improve member engagement, reduce churn, and differentiate itself from competitors that focus solely on coaching or medication access.
WW’s clinical segment has grown 60% year‑over‑year to 124,000 subscribers, and the addition of PVOLVE’s evidence‑based workouts is expected to accelerate that growth. The move supports WW’s broader strategy to strengthen its clinical business while maintaining a high‑value, integrated service offering that appeals to a rapidly expanding GLP‑1 market.
Investors responded positively to the announcement, reflecting confidence in WW’s integrated GLP‑1 strategy and the added value of a clinically validated strength‑training platform. The partnership positions WW as a leader in comprehensive weight health, combining medication, coaching, nutrition, and now strength training to enhance member outcomes and drive future growth.
Julie Rice, WW’s Chief Experience Officer, said the partnership “builds on our foundation by bringing more strength‑forward movement into our ecosystem alongside nutrition, behavior change, coaching, and medical care—so our members can achieve more sustainable, long‑term results.” Rachel Katzman, founder of PVOLVE, added that the collaboration “empowers people to feel strong, capable, and confident in their bodies through every stage of life.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.